NCT04901455View on ClinicalTrials.gov

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
COPD
Interventions
BIOLOGICAL

LAIV

Standard dose of LAIV administered by a licensed health care providers.

Trial Locations (1)

27514

RECRUITING

Eastowne Medical Office Building, Chapel Hill

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of North Carolina, Chapel Hill

OTHER